Skip to content

Clinical Evaluation of Enteral-extended Anti-reflux Stents for Pancreatic Pseudocyst

Clinical Evaluation of Enteral-extended Anti-reflux Stents for Pancreatic Pseudocyst

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05716594
Enrollment
52
Registered
2023-02-08
Start date
2023-03-01
Completion date
2025-12-31
Last updated
2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Pseudocyst

Brief summary

At present, endoscopic therapy is the preferred method to solve biliary or pancreatic diseases. And EUS-guided stent implantation and drainage of pancreatic pseudocyst is the main method in Endoscopic treatment of pancreatic pseudocyst. However, blockage of stent is a problem that has puzzled endoscopists for a long time. The mechanism of stent blockage is related to the reflux of gastrointestinal contents into the stent. Although plastic stents are widely used in patients who needed drainage. However, the average free time for stent is only 77 to 126 days, leading to the need for stent replacement in most patients within 3 months. As one end of the double pigtail stent used for drainage of pancreatic pseudocyst may be located in the stomach, it may cause the stent to be blocked by the contents of the stomach. Therefore, multiple stents or additional stents or drainage tube are often needed to further strengthen the drainage. It seems that the mechanism of stent blockage are associated with gastrointestinal contents reflux. And stents required be replaced again by endoscopic approach when jamming. However, EUS and ERCP are difficult, costly, and may be with complications. Additional operations will increase the risks and costs. Therefore, a stent that can effectively prevent reflux, solve clinical problems, and effectively prolong stent patency time is urgently needed.

Detailed description

At present, endoscopic therapy is the preferred method to solve biliary or pancreatic diseases. And EUS-guided stent implantation and drainage of pancreatic pseudocyst is the main method in Endoscopic treatment of pancreatic pseudocyst. However, blockage of stent is a problem that has puzzled endoscopists for a long time. The mechanism of stent blockage is related to the reflux of gastrointestinal contents into the stent. Although plastic stents are widely used in patients who needed drainage. However, the average free time for stent is only 77 to 126 days, leading to the need for stent replacement in most patients within 3 months. As one end of the double pigtail stent used for drainage of pancreatic pseudocyst may be located in the stomach, it may cause the stent to be blocked by the contents of the stomach. Therefore, multiple stents or additional stents or drainage tube are often needed to further strengthen the drainage. It seems that the mechanism of stent blockage are associated with gastrointestinal contents reflux. And stents required be replaced again by endoscopic approach when jamming. However, EUS and ERCP are difficult, costly, and may be with complications. Additional operations will increase the risks and costs. Therefore, a stent that can effectively prevent reflux, solve clinical problems, and effectively prolong stent patency time is urgently needed. The extended enteral anti-reflux stent developed by our research team has potential advantages in prolonging the patency period of the stent and preventing secondary infection of pseudocysts. In this study, we aim to evaluate the effect of the stent on the drainage of pancreatic pseudocyst.

Interventions

COMBINATION_PRODUCTPlant enteral-extended anti-reflux stents

Plant enteral-extended anti-reflux stents in EUS-guided drainage of pancreatic pseudocysts

COMBINATION_PRODUCTPlant traditional stents

Plant traditional stents in EUS-guided drainage of pancreatic pseudocysts

Sponsors

Peking University Third Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
12 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Pancreatic pseudocyst by a variety of causes, including acute pancreatitis, chronic pancreatitis, drug-induced pancreatitis * Pseudocyst compressed gastrointestinal or bile duct and causes obstruction symptoms or causes other symptoms * Diameter of pseudocyst \>6 cm with no compression symptoms, but progressively increases and is failed to conservatively treat

Exclusion criteria

* Wall-off necrosis with liquidation mimics pseudocyst * Pseudocyst formation ≤8 weeks, cyst wall is immature * Cannot puncture by EUS-guided approach for any reason * Patients with serious cardiovascular or cerebrovascular diseases or other diseases which are not fitted to anaesthetize * Severe coagulopathy or thrombocytopenia

Design outcomes

Primary

MeasureTime frameDescription
Disappearance rate of pseudocyst(PDR) after stent implantationin 6 monthsPDR=1-(Postoperative pseudocyst area/Preoperative pseudocyst area)×100%

Secondary

MeasureTime frameDescription
Time of disappearance of pseudocyst after stent implantationin 6 monthsTime of disappearance of pseudocyst after stent implantation

Countries

China

Contacts

Primary ContactYonghui Huang, archiater
chengzhuopku@163.com13911765322

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026